Post Concussive Symptoms Clinical Trial
Official title:
Neurofilament Light Chain, Inflammatory Markers, Calcitonin Gene-related Peptide, and Kynurenine Metabolites in Patients With Severe Post-concussive Symptoms
Verified date | February 2023 |
Source | University of Aarhus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study was to investigate the biomarkers, neurofilament light chain, inflammatory markers, calcitonin-gene-related peptide, and metabolites from the kynurenine pathway in patients with severe post-concussive symptoms. The main question it aimed to answer was: - Are the biomarker concentrations significantly changed in patients with severe post-concussive symptoms compared to healthy individuals? - Do the biomarker concentrations change at follow-up? Participants were recruited from a recently published randomized controlled trial (Clinicaltrials.gov no. NCT02337101 / PMID: 31891145 ). The biomarker concentrations were compared to a healthy control group recruited from the Blood Bank at Aarhus University Hospital in 2022.
Status | Completed |
Enrollment | 86 |
Est. completion date | July 2023 |
Est. primary completion date | July 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 30 Years |
Eligibility | Patients with severe post-concussive symptoms: Inclusion Criteria: 1. Concussion caused by a head trauma based on the diagnostic criteria recommended by the World Health Organization (WHO) Task Force 2. Age between 18 and 30 years 3. Able to understand, speak and read Danish. 4. A score of 20 or more on the Rivermead Post Concussion Symptoms Questionnaire (RPQ). Exclusion Criteria: 1. Objective neurological findings indicating neurological disease or brain damage. 2. Previous concussion leading to persistent post-concussional symptoms within the last two years. 3. Severe misuse of alcohol, prescription drugs and / or illegal drugs. 4. Severe psychiatric, neurological,or other medical disease that would impede participation in the intervention 5. Inability to speak and read Danish Healthy control group (recruited from December 2021 - March 2022): - Individuals from the Blood Bank at Aarhus University Hospital in Denmark. Inclusion criteria were: 1. Age between 18-30 years 2. Equal distribution between the genders (60 men and 60 women). This number was based on a power analysis using published data from neurofilament light chain. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University of Aarhus | Direktør Emil C. Hertz og Hustru Inger Hertz Fond, Fonden til Lægevidenskabens Fremme, Helga Og Peter Kornings Fond, Region MidtJylland Denmark, Sygekassernes Helsefond |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Neurofilament light chain at baseline (primary outcome) | The investigators hypothesized:
The concentration of neurofilament light chain (ng/L) is significantly increased at baseline in patients compared to the healthy control group. |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Primary | Neurofilament light chain at follow-up (primary outcome) | The investigators hypothesized:
1)The neurofilament light chain concentration (ng/L) normalizes (decreases) at follow-up compared to the baseline concentration in patients. |
The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample. | |
Primary | Self-reported post-concussion symptoms score (primary outcome) | The symptom score was measured at both baseline and follow-up using the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) which is a self-reported questionnaire. The Rivermead Post-Concussion Symptoms Questionnaire contains 16 items which is rated from 0 (not experienced) to 4 (a severe problem).
The total score thus ranges on a scale between 0-64. |
The baseline symptom score (RPQ) was obtained from the patients up to 7 months after the concussion (4 months median), and the follow-up score was obtained up to 16 months (10.5 median) after the concussion | |
Primary | Calcitonin-gene related peptide at baseline (CGRP) | The investigators hypothesized:
The concentration of calcitonin gene-related peptide (pg/mL) is decreased compared to the healthy control group at baseline |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Primary | Calcitonin-gene related peptide at follow-up (CGRP) | The investigators hypothesized:
The CGRP concentrations (pg/mL) will normalize (increase) at follow-up compared to baseline. |
The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample. | |
Secondary | Quinolinic acid at baseline | The investigators hypothesized that:
The concentration of the neurotoxic metabolite, quinolinic acid (measured in nM), is increased in patients compared to healthy controls |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Secondary | Quinolinic acid at follow-up | The investigators hypothesized:
The quinolinic acid concentration (nM) normalizes (decreases) at follow-up compared to the baseline concentration. |
The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample. | |
Secondary | Neuroprotective index at baseline | The investigators hypothesized:
The ratio between the neuroprotective metabolite kynurenic acid (KYNA) and the neurotoxic metabolite quinolinic acid (KynA/QUIN) is lower than the ratio in healthy individuals at baseline. A higher ratio means a better outcome. |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Secondary | Neuroprotective index at follow-up | The investigators hypothesized:
The ratio between the neuroprotective metabolite kynurenic acid (KYNA) and the neurotoxic metabolite quinolinic acid (QUIN) normalizes (increases) at follow-up compared to baseline. A higher ratio thus means a better outcome. |
The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample. | |
Secondary | Inflammatory markers at baseline | The investigators hypothesized that:
Tumor necrosis factor alpha (TNF-a) and interleukin-6 (IL-6) (both pg/mL) are increased in patients compared to healthy controls. |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Secondary | Inflammatory markers at baseline | The investigators hypothesized:
Basic fibroblast growth factor (Basic FGF), Eotaxin, interferon gamma (IFN-y), interleukin 1 beta (IL-1B), interleukin 8 (IL-8), interleukin 9 (IL-9), interleukin 17 (IL17), Interferon gamma-induced protein 10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), and Macrophage Inflammatory Protein beta (MIP-1b) (all pg/mL) are significantly increased in patients compared to controls (hypothesis is based on a recent study (PMID: 32326805) |
The baseline blood sample was taken up to 7 months after the concussion (4 months median). | |
Secondary | Inflammatory markers at follow-up | TNF-a and IL-6 (both pg/mL) decreases at follow-up compared to the baseline value in patients. | The follow-up blood sample was taken up to 12 months after baseline (7 months median) after the baseline blood sample. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02613936 -
Transcranial Direct Current Stimulation for the Treatment of Deficits After Traumatic Brain Injury
|
N/A | |
Not yet recruiting |
NCT06413173 -
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
|
N/A |